ClinicalTrials.gg

Program

vepdegestrant

Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.

Its studies are mostly in Breast Neoplasms, led by 3 companies.

Furthest: phase 3, since Nov 16, 202220 company-led studies, 6 open or runningNext primary completion: Dec 4, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer176 open or runningphase 3since Nov 16, 2022Jul 14, 2022Dec 4, 2026phase 1 · NCT07231991
Arvinas Estrogen Receptor20 open or runningphase 2since Aug 27, 2019Aug 27, 2019none ahead
Arvinas10 open or runningphase 2since Sep 7, 2022Sep 7, 2022none ahead

Also a collaborator on its studies: carrick-therapeutics-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Aug 27, 2019.

  1. Oct 5, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05573555 · 20 enrolled · United States, Canada, Italy and more
  2. Nov 16, 2022Phase 3 study in Breast NeoplasmsPfizer · NCT05654623 · 624 enrolled · United States, Argentina, Australia and more
  3. Dec 7, 20222 phase 1 studies in HealthyPfizer · NCT05652660, NCT05673889
  4. Jan 17, 2023Phase 1 study in Breast NeoplasmsPfizer · NCT05732428 · 9 enrolled · China
  5. May 25, 2023Phase 3 study in Breast NeoplasmsPfizer · NCT05909397 · 59 enrolled · United States, Australia, Brazil and more
  6. Jun 8, 2023Phase 1 study in HealthyPfizer · NCT05930925 · 12 enrolled · United States
  7. Aug 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06005688 · 12 enrolled · Belgium
  8. Oct 16, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06125522 · 11 enrolled · United States, Belgium, France and more
  9. Dec 13, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06206837 · 71 enrolled · United States, Belgium, Canada and more
  10. Feb 5, 20242 phase 1 studiesPfizer · NCT06256510, NCT06275841
  11. Mar 28, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT06911788 · 10 enrolled · Netherlands
  12. Nov 13, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT07231991 · 24 planned · United States
  13. Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT05573555 · “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to…”
  14. Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT06125522 · “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to …”

Ahead

  1. Dec 4, 2026Primary completion: phase 1 study in Healthy ParticipantsPfizer · NCT07231991
  2. Dec 30, 2026Primary completion: phase 3 study in Breast NeoplasmsPfizer · NCT05909397
  3. Mar 24, 2027Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05548127

TargetBeta

ESR1 →read by rule
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07231991Healthy Participants · United States1RecruitingPfizerDec 4, 202624
NCT06911788Healthy Participants · Netherlands1CompletedPfizerMay 23, 202510
NCT06275841Healthy · United States1CompletedPfizerMay 3, 202412
NCT06256510Healthy Participants · Belgium1CompletedPfizerApr 16, 202415
NCT06206837Breast Neoplasms · United States, Belgium, Canada and more2Active, not recruitingPfizerSep 5, 202571
NCT06125522Breast Neoplasms · United States, Belgium, France and more2TerminatedPfizerSep 10, 202611
NCT06005688Healthy Participants · Belgium1CompletedPfizerOct 11, 202312
NCT05930925Healthy · United States1CompletedPfizerJul 27, 202312
NCT05909397Breast Neoplasms · United States, Australia, Brazil and more3Active, not recruitingPfizerDec 30, 202659
NCT05732428Breast Neoplasms · China1CompletedPfizerMar 29, 20249
NCT05673889Healthy · Belgium1CompletedPfizerMar 15, 202324
NCT05652660Healthy · United States1CompletedPfizerFeb 9, 202312
NCT05654623Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerJan 31, 2025624
NCT05573555Breast Neoplasms · United States, Canada, Italy and more2TerminatedPfizerOct 6, 202620
NCT05538312Healthy · Belgium1CompletedPfizerApr 24, 202312
NCT05549505Breast Neoplasms · United States, Georgia, Germany and more2CompletedArvinasJul 13, 2024152
NCT05548127Breast Neoplasms · United States, Canada, Italy and more2Active, not recruitingPfizerMar 24, 202737
NCT05501769Breast Neoplasms · United States, Spain1CompletedArvinas Estrogen ReceptorJul 3, 202432
NCT05463952Breast Neoplasms · Japan1Active, not recruitingPfizerMay 4, 20236
NCT04072952Breast Neoplasms · United States2CompletedArvinas Estrogen ReceptorSep 13, 2024219

How it is read

Names in the registry

  • “ARV-471”, 7 entries
  • “vepdegestrant”, 6 entries
  • “Vepdegestrant”, 4 entries
  • “[phenyl-14C]ARV-471”, 1 entry
  • “[oxoisoindolin-14C]ARV-471”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.